2 active not recruiting. 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Active not recruiting 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Clear Cell Adenocarcinoma: new trials by email Literature Review of Clear Cell Adenocarcinoma trials Research Report on Clear Cell Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas Nivolumab, Ipilimumab - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Active not recruiting | Brown University | 46 | 2018-04-30 | 2026-08-20 |
| Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Bevacizumab, Carboplatin, Docetaxel - Clear Cell Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 1052 | 2007-12-06 | 2025-12-30 |
Adenocarcinoma, Clear Cell (2) · Fallopian Tube Neoplasms (2) · Ovarian Neoplasms (2) · Adenocarcinoma, Mucinous (1) · Brenner Tumor (1) · Carcinoma (1) · Recurrence (1)
Adenocarcinoma (2) · Adnexal Diseases (2) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Fallopian Tube Diseases (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Genital Diseases (2) · Genital Diseases, Female (2) · Genital Neoplasms, Female (2) · Gonadal Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Neoplasms, Glandular and Epithelial (2)
Bevacizumab (1) · Carboplatin (1) · Disulfides (1) · Docetaxel (1) · Gemcitabine (1) · Immunoglobulin G (1) · Ipilimumab (1) · Nivolumab (1) · Paclitaxel (1) · Taxes (1)
Brown University (1) · National Cancer Institute (NCI) (1)
United States (2) · Japan (1) · South Korea (1)
Don Dizon, MD (1) · Robert L Coleman (1)
PMID 28438473, PMID 31722153, PMID 37185961
U10CA027469 (1), U10CA180868 (1)